The role of combined oral contraceptives in the management of acne and seborrhea

European Journal of Contraception and Reproductive Health Care

Volumn 9, Issue 2, 2004, Pages 107-124

  Del Marmol, V ^a   Teichmann, A ^b   Gertsen, K ^c,d  

^a ERASME HOSPITAL   (Belgium)

^b KLINIKUM ASCHAFFENBURG   (Germany)

^c NV ORGANON   (Netherlands)

^d NONE   (Netherlands)

Author keywords

Acceptability; Acne; Desogestrel; Oral contraceptives; Progestogens; Safety; Seborrhea; Women

Indexed keywords

CHLORMADINONE ACETATE; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; NORGESTIMATE; NOVIAL; ORAL CONTRACEPTIVE AGENT; TRI CILEST; TRI MERCI; TRIMIRON;

ACNE; BREAST TENDERNESS; CLINICAL TRIAL; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; HEADACHE; HUMAN; LOW DRUG DOSE; NAUSEA; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SEBORRHEA; UPPER RESPIRATORY TRACT INFECTION; VAGINITIS;

EID: 3042698759     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/1362518042000221508     Document Type: Review

References (85)

1. Goodman GJ. Post-acne scarring: a short review of its pathophysiology. Aust J Dermatol 2001;42:84-90
2. Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 1990;69:61-5
3. Bershad SV. The modern age of acne therapy: a review of current treatment options. Mt Sinai J Med 2001;68:279-86
4. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and therapies. Semin Cutan Med Surg 2001;20:144-53
5. Jemec GB, Linneberg A, Nielsen NH, Frolund L, Madsen F, Jorgensen T. Have oral contraceptives reduced the prevalence of acne? A population-based study of acne vulgaris, tobacco smoking and oral contraceptives. Dermatology 2002;204:179-84
6. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999;41:577-80
7. Kligman AM. Postadolescent acne in women. Cutis 1991;48:75-7
8. Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001;15:541-5
9. Burton JL, Shuster S. The relationship between seborrhoea and acne vulgaris. Br J Dermatol 1971;85:197-8
10. Pierard GE, Pierard-Franchimont C, Le T. Seborrhoea in acne-prone and acne-free patients. Dermatologica 1987;175:5-9
11. Wellings D, Blades R, Koelink S, Keder C, Doel SV. Doctors vs. women: misconceptions on the importance of skin. Presented at 17th World Congress of Fertility and Sterility, Melbourne, 2001:22
12. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985;20:425-9
13. Niemeier V, Kupfer J, Demmelbauer-Ebner M, Stangier U, Effendy I, Gieler U. Coping with acne vulgaris. Evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology 1998;196:108-15
14. Kilkenny M, Merlin K, Plunkett A, Marks R. The prevalence of common skin conditions in Australian school students. 3. Acne vulgaris. Br J Dermatol 1998;139:840-5
15. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986;115:386
16. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998;134:454-8
17. Anderson R, Rajagopalan R. Responsiveness of the Dermatology-specific Quality of Life (DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial. Qual Life Res 1998;7:723-34
18. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996;107:707-13
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16
20. Girman CJ, Hartmaier S, Thiboutot D, et al. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res 1996;5:481-90
21. Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol 1998;78:451-6
22. Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne - assessment of a new acne-specific questionnaire. Clin Exp Dermatol 2001;26:380-5
23. Salek MS, Khan GK, Finlay AY. Questionnaire techniques in assessing acne handicap: reliability and validity study. Qual Life Res 1996;5:131-8
24. Aktan S, Ozmen E, Sanli B. Anxiety, depression, and nature of acne vulgaris in adolescents. Int J Dermatol 2000;39:354-7
25. Gupta MA, Gupta AK. The psychological comorbidity in acne. Clin Dermatol 2001;19:360-63
26. Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol 2001;2:135-41
27. Madden WS, Landells ID, Poulin Y, et al. Treatment of acne vulgaris and prevention of acne scarring: Canadian consensus guidelines. J Cutan Med Surg 2000;4(Suppl 1):S2-13
28. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology 2003;206:57-67
29. Shaw JC. Hormonal therapy in dermatology. Dermatol Clin 2001;19:169-78
30. Pye RJ, Meyrick G, Pye MJ, Burton JL. Effect of oral contraceptives on sebum excretion rate. Br Med J 1977;2:1581-2
31. Pasquale SA. Rationale for a triphasic oral contraceptive. J Reprod Med 1984;29:560-7
32. Newton JR. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995 1:231-63
33. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception 1988;38:325-32
34. Witkowski JA, Parish LC. From other ghosts of the past: acne lesion counting. J Am Acad Dermatol 1999;40:131
35. Lucky AW, Barber BL, Girman CJ, Williams J, Ratterman J, Waldstreicher J. A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol 1996;35:559-65
36. Lucchina LC, Kollias N, Gillies R, et al. Fluorescence photography in the evaluation of acne. J Am Acad Dermatol 1996; 35:58-63
37. Rizova E, Kligman A. New photographic techniques for clinical evaluation of acne. J Eur Acad Dermatol Venereol 2001;15(Suppl 3):13-18
38. Phillips SB, Kollias N, Gillies R, Muccini JA, Drake LA. Polarized light photography enhances visualization of inflammatory lesions of acne vulgaris. J Am Acad Dermatol 1997;37:948-52
39. Allen BS, Smith JG, Jr. Various parameters for grading acne vulgaris. Arch Dermatol 1982;118:23-5
40. Burke BM, Cunliffe WJ. The assessment of acne vulgaris - the Leeds technique. Br J Dermatol 1984;111:83-92
41. Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol 1979;115:571-5
42. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-22
43. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand Suppl 1986;134:29-32
44. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54
45. Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care 2001;6:46-53
46. Vree ML, Schmidt J. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany. Eur J Contracept Reprod Health Care 2001;6:108-14
47. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25-34
48. Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996;53:163-70
49. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud 1996;41:423-9
50. Halbe HW, de Melo NR, Bahamondes L, et al. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care 1998; 3:113-20
51. Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S. Multicenter trial of two monophasic oral contraceptives containing 30 meg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception 1995;51:225-9
52. Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen. Contraception 1992;46:477-88
53. Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TC. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care 2000;5:248-55
54. Prilepskaya VN, Serov VN, Zharov EV, et al. Effects of a phasic oral contraceptive containing desogestrel on facial seborrhea and acne. Contraception 2003;68:239-45
55. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15
56. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001;203:38-44
57. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998;57:103-9
58. Colver GB, Mortimer PS, Dawber RP. Cyproterone acetate and two doses of oestrogen in female acne; a double-blind comparison. Br J Dermatol 1988;118:95-9
59. Fugère P, Percival-Smith RK, Lussier-Cacan S, Davignon J, Farquhar D. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception 1990;42:225-34
60. Gollnick H, Albring M, Brill K. The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. Ann Endocrinol (Paris) 1999;60:157-66
61. Aydinlik S, Kaufman J, Lachnit-Fixson U, Lehnert J. Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-oestrogen combination. Clin Trials J 1990;27:392-402
62. Falsetti L. Acne treatment with a new estroprogestinic biphasic combination containing desogestrel. Acta Eur Fertil 1991;22:283-6
63. Kuhnz W, Blode H, Mahler M. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contraception 1994;49:255-63
64. Piérard-Franchimont C, Gaspard U, Lacante P, Rhoa M, Slachmuylders P, Pierard GE. A quantitative biometrological assessment of acne and hormonal evaluation in young women using a triphasic low-dose oral contraceptive containing gestodene. Eur J Contracept Reprod Health Care 2000;5:275-86
65. Volpe A, Silferi M, Mauri A, et al. Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel. Eur J Obstet Gynecol Reprod Biol 1994;53:205-9
66. Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994;50:373-82
67. Kasper P. Cyproterone acetate: a genotoxic carcinogen? Pharmacol Toxicol 2001;88:223-31
68. Ohri SK, Gaer JA, Keane PF. Hepatocellular carcinoma and treatment with cyproterone acetate. Br J Urol 1991;67:213
69. Rudiger T, Beckmann J, Queisser W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol. Lancet 1995;345:452-3
70. Watanabe S, Yamasaki S, Tanae A, Hibi I, Honna T. Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc Committee on Androcur Users. Lancet 1994;344:1567-8
71. The Collaborative MILTS Project Team, Heinemann LAJ, DoMinhc T, Guggenmoos-Holzmann I, et al. Oral contraceptives and liver cancer. Results of the Multicenter International Liver Tumor Study (MILTS). Contraception 1997;56:275-84
72. Regidor PA, Speer K, Regidor M, Schindler EM. Long-term side-effects following cyproterone acetate containing therapy in gynecology. Zentralbl Gynakol 2000;122:268-73
73. Pymar HC, Creinin MD. The risks of oral contraceptive pills. Semin Reprod Med 2001;19:305-12
74. Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet. Gynecol Reprod Biol 2001;95:193-7
75. Gris JC, Jamin C, Benifla JL, Quere I, Madelenat P, Mares P. APC resistance and third-generation oral contraceptives: acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease. Hum Reprod 2001;16:3-8
76. Heinemann LA. Emerging evidence on oral contraceptives and arterial disease. Contraception 2000;62:29-36S
77. Chasan-Taber L, Willett WC, Stampfer MJ, et al. Oral contraceptives and ovulatory causes of delayed fertility. Am J Epidemiol 1997;146:258-65
78. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32
79. Smith JS, Green J, Berrington dG, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159-67
80. Stanford JL. Oral contraceptives and neoplasia of the ovary. Contraception 1991;53:543-56
81. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study. Br J Cancer 1995;71:1340-2
82. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol 2000;152:233-41
83. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 2002;65:407-10
84. Cobb KL, Kelsey JL, Sidney S, Ettinger B, Lewis CE. Oral contraceptives and bone mineral density in white and black women in CARDIA. Coronary Risk Development in Young Adults. Osteoporos Int 2002;13:893-900
85. Oddens BJ, Arnolds HT, Van Maris MG, Van Lunsen HW. The dynamics of oral contraceptive use in The Netherlands 1990-1993. Adv Contracept 1994;10:167-74